Free Trial
NASDAQ:CTNM

Contineum Therapeutics Q1 2025 Earnings Report

Contineum Therapeutics logo
$4.75 +0.60 (+14.46%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$4.76 +0.01 (+0.21%)
As of 06/6/2025 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Contineum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Contineum Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Contineum Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 4:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Contineum Therapeutics Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Contineum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email.

About Contineum Therapeutics

Contineum Therapeutics (NASDAQ:CTNM), a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

View Contineum Therapeutics Profile

More Earnings Resources from MarketBeat